We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 80.73%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
26
DELISTED
MEDIVATION, INC.
MDVN
$19.9M 0.21%
329,876
– –
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$19.3M 0.2%
2,475,515
– –
NVAX icon
28
Novavax
NVAX
$1.22B
$17.3M 0.18%
118,963
– –
PGNX
29
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$16.8M 0.18%
3,970,250
-380,558
-9% -$1.84M
XNCR icon
30
Xencor
XNCR
$1.46B
$16.6M 0.17%
872,072
– –
HALO icon
31
Halozyme
HALO
$9.92B
$15.9M 0.17%
1,838,057
-93,000
-5% -$918K
ARRY
32
DELISTED
Array Biopharma Inc
ARRY
$15.3M 0.16%
4,310,666
– –
INSM icon
33
Insmed
INSM
$22.7B
$14.8M 0.16%
1,500,000
– –
DSCI
34
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$14.8M 0.16%
3,752,390
– –
LKFT
35
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
$14.4M 0.15%
259,894
-43,500
-14% -$2.19M
FOMX
36
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$14.2M 0.15%
2,241,702
– –
BLUE
37
DELISTED
bluebird bio
BLUE
$12.7M 0.13%
22,692
-4,555
-17% -$2.58M
MRTX
38
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$12.4M 0.13%
2,269,198
-999,358
-31% -$15.9M
TGTX icon
39
TG Therapeutics
TGTX
$8.37B
$12.1M 0.13%
2,003,991
– –
ALKS icon
40
Alkermes
ALKS
$8.27B
$10.8M 0.11%
250,251
– –
ACGN
41
DELISTED
Aceragen Inc
ACGN
$10.7M 0.11%
51,529
+79
+0.2% +$17.4K
ARCT icon
42
Arcturus Therapeutics
ARCT
$166M
$10.5M 0.11%
333,766
– –
ASND icon
43
Ascendis Pharma A/S
ASND
$16.7B
$9.89M 0.1%
745,521
+240,000
+47% +$3.7M
MGNX icon
44
MacroGenics
MGNX
$239M
$9.82M 0.1%
363,676
– –
DERM
45
DELISTED
Dermira, Inc.
DERM
$9.55M 0.1%
326,428
+51,428
+19% +$1.42M
IMGN
46
DELISTED
Immunogen Inc
IMGN
$9.29M 0.1%
3,015,353
-1,437,092
-32% -$9.01M
MRUS
47
DELISTED
Merus
MRUS
$8.97M 0.09%
+1,122,859
New +$9.82M
LGND icon
48
Ligand Pharmaceuticals
LGND
$5.86B
$8.75M 0.09%
117,638
– –
AGIO icon
49
Agios Pharmaceuticals
AGIO
$2.11B
$8.71M 0.09%
207,915
-100,000
-32% -$4.94M
ZGNX
50
DELISTED
Zogenix, Inc.
ZGNX
$8.05M 0.08%
1,000,000
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Baker Bros. Advisors held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Intellia Therapeutics worth $22.7M.

  • Baker Bros. Advisors's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Baker Bros. Advisors's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Baker Bros. Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Baker Bros. Advisors opened 10 new positions and closed 7 in Q2 2016.
  • Baker Bros. Advisors's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.